Reddy Janardan K, Rao M Sambasiva
Department of Pathology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Avenue, Chicago, IL 60611-3008, USA.
Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G852-8. doi: 10.1152/ajpgi.00521.2005.
Fatty liver disease (FLD), whether it is alcoholic FLD (AFLD) or nonalcoholic FLD (NAFLD), encompasses a morphological spectrum consisting of hepatic steatosis (fatty liver) and steatohepatitis. FLD has the inherent propensity to progress toward the development of cirrhosis and hepatocellular carcinoma. It is generally difficult to distinguish AFLD from NAFLD on morphological grounds alone despite the distinctions implied by these etiological designations. The indistinguishable spectrum of histological features of both AFLD and NAFLD suggests a possible convergence of pathogenetic mechanisms at some critical juncture that enables the progression of steatohepatitis toward cirrhosis and liver cancer. From a pathogenetic perspective, FLD may be considered a single disease with multiple etiologies. Excess energy consumption and reduced energy combustion appear to be critical events that culminate in lipid storage in the liver. Energy combustion in the liver is controlled by peroxisome proliferator-activated receptor (PPAR)-alpha-regulated mitochondrial and peroxisomal fatty acid beta-oxidation systems and the microsomal omega-oxidation system. PPAR-alpha, a receptor for peroxisome proliferators, functions as a sensor for fatty acids (lipid sensor), and ineffective PPAR-alpha sensing can lead to reduced energy burning resulting in hepatic steatosis and steatohepatitis. Delineation of the pathogenetic aspects of FLD is necessary for developing novel therapeutic strategies for this disease.
脂肪性肝病(FLD),无论是酒精性脂肪性肝病(AFLD)还是非酒精性脂肪性肝病(NAFLD),都包含一个由肝脂肪变性(脂肪肝)和脂肪性肝炎组成的形态学谱。FLD有向肝硬化和肝细胞癌发展的内在倾向。尽管这些病因学名称暗示了区别,但仅从形态学角度通常很难区分AFLD和NAFLD。AFLD和NAFLD难以区分的组织学特征谱表明,在某些关键节点,致病机制可能会趋同,从而使脂肪性肝炎向肝硬化和肝癌发展。从致病角度来看,FLD可被视为一种具有多种病因的单一疾病。能量消耗过多和能量燃烧减少似乎是导致肝脏脂质蓄积的关键事件。肝脏中的能量燃烧由过氧化物酶体增殖物激活受体(PPAR)-α调节的线粒体和过氧化物酶体脂肪酸β-氧化系统以及微粒体ω-氧化系统控制。PPAR-α是过氧化物酶体增殖物的受体,作为脂肪酸传感器(脂质传感器)发挥作用,PPAR-α感应功能失效会导致能量燃烧减少,从而导致肝脂肪变性和脂肪性肝炎。明确FLD的致病机制对于开发针对该疾病的新治疗策略至关重要。